214 related articles for article (PubMed ID: 12434264)
1. [Current aspects of the diagnosis of malignant hyperthermia].
Rüffert H; Olthoff D; Deutrich C; Froster UG
Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
[TBL] [Abstract][Full Text] [Related]
3. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
4. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of disposition for malignant hyperthermia--an updated review based on 1,001 studies].
Olthoff D; Deutrich C; Meinecke CD
Anaesthesiol Reanim; 1997; 22(2):32-40. PubMed ID: 9235003
[TBL] [Abstract][Full Text] [Related]
6. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
Heytens L
Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
[TBL] [Abstract][Full Text] [Related]
8. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
9. Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
[TBL] [Abstract][Full Text] [Related]
10. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
12. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale].
von Richthofen V; Wappler F; Scholz J; Fiege M; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Apr; 33(4):244-9. PubMed ID: 9617423
[TBL] [Abstract][Full Text] [Related]
14. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
[TBL] [Abstract][Full Text] [Related]
15. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
Rueffert H; Olthoff D; Deutrich C; Froster UG
Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
[TBL] [Abstract][Full Text] [Related]
16. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
[TBL] [Abstract][Full Text] [Related]
17. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
Steinfath M; Scholz J; Singh S; Wappler F
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
[TBL] [Abstract][Full Text] [Related]
18. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia.
Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM
Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
20. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
